111 Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
111 Capital's XBI Position: Q2 2026 in Review
111 Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 137% in Q2 2026, buying an estimated $1.64M and bringing the position to 21,034 shares worth $3.33M. The position accounts for 0.57% of the portfolio, ranked #33.
111 Capital first reported a position in XBI in Q1 2026 and has held it in 2 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- 111 Capital held 21,034 shares of State Street SPDR S&P Biotech ETF worth $3.33M as of Q2 2026.
- 111 Capital bought 12,144 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.64M.
- State Street SPDR S&P Biotech ETF made up 0.57% of 111 Capital's portfolio in Q2 2026, its #33 holding.
- 111 Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2026 and has held it in 2 quarters since.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.